Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.57 - $27.34
Previous CloseN/A
Volume680.40K
Average Volume (3M)1.84M
Market Cap
$2.20B
Enterprise Value$1.36B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$388.24M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 07, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.75
Shares Outstanding138,100,430
10 Day Avg. Volume2,477,520
30 Day Avg. Volume1,839,164
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda-19.93
Forecast
1Y Price Target
$37.50Price Target Upside127.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe deal brought in $825M of upfront cash, annual payments of $50M beginning Feb 2026, and $100M + $200M in clinical trial enrollment milestones for ARO-DM1 that Arrowhead expects to meet within a year.
PartnershipsRecent developments continue to reinforce the strength and strategic value of its collaboration with Sarepta Therapeutics, which remains symbiotic and mutually beneficial.
Pipeline AdvancementArrowhead enters its F2H25 with accelerating momentum across its RNAi pipeline, led by the anticipated U.S. launch of plozasiran for FCS and supported by a robust portfolio of late-stage, early-stage, and partnered programs spanning cardiometabolic, pulmonary, muscular, adipose, and CNS diseases.
Bears Say
Equity Investment ConcernsArrowhead Pharmaceuticals, Inc. shares have been volatile due to fears of near-term selling pressure if SRPT monetized its equity investment.
Partnership RisksIf SRPT may choose to abandon the partnership entirely, this would leave ARWR without a key source of cash.
Regulatory UncertaintyUncertainty remains high due to questions around patient/physician demand, lingering safety concerns, and an unpredictable FDA affecting Elevidys uptake.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $27.34 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $2.20B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is tomorrow.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on May 12, 2025. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of -$0.187 by $2.937.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.95.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 138,100,430 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of $2.75 in its last earnings report, beating expectations of -$0.187. Following the earnings report the stock price went up 9.377%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
Arrowhead Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.50 (127.83% Upside)
$37.50 (127.83% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 553.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.20%
12-Months-Change
Fundamentals
Return on Equity
-24.67%
Trailing 12-Months
Asset Growth
64.74%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. The company focuses on creating medicines that silence disease-causing genes, primarily targeting liver diseases, as well as other indications. Arrowhead's proprietary Targeted RNAi Molecule (TRiM) platform aids in the design and delivery of these therapies, allowing for precise targeting of specific cells and tissues. The company is headquartered in Pasadena, California, and operates within the broader biotechnology and pharmaceuticals sector.
ARWR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Arrowhead Pharmaceuticals demonstrated strong financial performance and significant progress in its pipeline, particularly with the upcoming launch of Plozasiran and promising data from clinical trials. However, the company faces regulatory uncertainties and market challenges, with a heavy reliance on partnerships for future revenue. The sentiment is generally positive due to the outweighing highlights.Read More>ARWR Stock 12 Month Forecast
Average Price Target
$37.50
▲(127.83%Upside)
Technical Analysis
Agios Pharma
―
Beam Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―
Ownership Overview
4.15% Insiders
15.88% Mutual Funds
0.15% Other Institutional Investors
54.16% Public Companies and Individual Investors